Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Search

Page Path
HOME > Search
7 "Hanjong Ahn"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Original Articles
Genitourinary cancer
Bilateral Seminal Vesicle Invasion as a Strong Prognostic Indicator in T3b Prostate Cancer Patients Following Radical Prostatectomy: A Comprehensive, Multicenter, Long-term Follow-up Study
Jungyo Suh, In Gab Jeong, Hwang Gyun Jeon, Chang Wook Jeong, Sangchul Lee, Seong Soo Jeon, Seok-Soo Byun, Cheol Kwak, Hanjong Ahn
Cancer Res Treat. 2024;56(3):885-892.   Published online January 5, 2024
DOI: https://doi.org/10.4143/crt.2023.1264
AbstractAbstract PDFPubReaderePub
Purpose
Pathologic T3b (pT3b) prostate cancer, characterized by seminal vesicle invasion (SVI), exhibits variable oncological outcomes post–radical prostatectomy (RP). Identifying prognostic factors is crucial for patient-specific management. This study investigates the impact of bilateral SVI on prognosis in pT3b prostate cancer.
Materials and Methods
We evaluated the medical records of a multi-institutional cohort of men who underwent RP for prostate cancer with SVI between 2000 and 2012. Univariate and multivariable analyses were performed using Kaplan-Meier analysis and covariate-adjusted Cox proportional hazard regression for biochemical recurrence (BCR), clinical progression (CP), and cancer-specific survival (CSS).
Results
Among 770 men who underwent RP without neo-adjuvant treatment, median follow-up was 85.7 months. Patients with bilateral SVI had higher preoperative prostate-specific antigen levels and clinical T category (all p < 0.001). Extracapsular extension, tumor volume, lymph node metastasis (p < 0.001), pathologic Gleason grade group (p < 0.001), and resection margin positivity (p < 0.001) were also higher in patients with bilateral SVI. The 5-, 10-, and 15-year BCR-free survival rates were 23.9%, 11.7%, and 8.5%; CP-free survival rates were 82.8%, 62.5%, and 33.4%; and CSS rates were 96.4%, 88.1%, and 69.5%, respectively. The bilateral SVI group demonstrated significantly lower BCR-free survival rates, CP-free survival rates, and CSS rates (all p < 0.001). Bilateral SVI was independently associated with BCR (hazard ratio, 1.197; 95% confidence interval, p=0.049), CP (p=0.022), and CSS (p=0.038) in covariate-adjusted Cox regression.
Conclusion
Bilateral SVI is a robust, independent prognostic factor for poor oncological outcomes in pT3b prostate cancer.

Citations

Citations to this article as recorded by  
  • Role of [18F]-PSMA-1007 PET radiomics for seminal vesicle invasion prediction in primary prostate cancer
    Liang Luo, Xinyi Wang, Hongjun Xie, Hua Liang, Jungang Gao, Yang Li, Yuwei Xia, Mengmeng Zhao, Feng Shi, Cong Shen, Xiaoyi Duan
    Computers in Biology and Medicine.2024; 183: 109249.     CrossRef
  • 3,917 View
  • 125 Download
  • 1 Crossref
Close layer
Oncological Outcomes in Men with Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide with versus without Confirmatory Bone Scan
Chang Wook Jeong, Jang Hee Han, Dong Deuk Kwon, Jae Young Joung, Choung-Soo Kim, Hanjong Ahn, Jun Hyuk Hong, Tae-Hwan Kim, Byung Ha Chung, Seong Soo Jeon, Minyong Kang, Sung Kyu Hong, Tae Young Jung, Sung Woo Park, Seok Joong Yun, Ji Yeol Lee, Seung Hwan Lee, Seok Ho Kang, Cheol Kwak
Cancer Res Treat. 2024;56(2):634-641.   Published online December 5, 2023
DOI: https://doi.org/10.4143/crt.2023.848
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
In men with metastatic castration-resistant prostate cancer (mCRPC), new bone lesions are sometimes not properly categorized through a confirmatory bone scan, and clinical significance of the test itself remains unclear. This study aimed to demonstrate the performance rate of confirmatory bone scans in a real-world setting and their prognostic impact in enzalutamide-treated mCRPC.
Materials and Methods
Patients who received oral enzalutamide for mCRPC during 2014-2017 at 14 tertiary centers in Korea were included. Patients lacking imaging assessment data or insufficient drug exposure were excluded. The primary outcome was overall survival (OS). Secondary outcomes included performance rate of confirmatory bone scans in a real-world setting. Kaplan-Meier analysis and multivariate Cox regression analysis were performed.
Results
Overall, 520 patients with mCRPC were enrolled (240 [26.2%] chemotherapy-naïve and 280 [53.2%] after chemotherapy). Among 352 responders, 92 patients (26.1%) showed new bone lesions in their early bone scan. Confirmatory bone scan was performed in 41 patients (44.6%), and it was associated with prolonged OS in the entire population (median, 30.9 vs. 19.7 months; p < 0.001), as well as in the chemotherapy-naïve (median, 47.2 vs. 20.5 months; p=0.011) and post-chemotherapy sub-groups (median, 25.5 vs. 18.0 months; p=0.006). Multivariate Cox regression showed that confirmatory bone scan performance was an independent prognostic factor for OS (hazard ratio 0.35, 95% confidence interval, 0.18 to 0.69; p=0.002).
Conclusion
Confirmatory bone scan performance was associated with prolonged OS. Thus, the premature discontinuation of enzalutamide without confirmatory bone scans should be discouraged.

Citations

Citations to this article as recorded by  
  • ECM-mimicking hydrogel models of human adipose tissue identify deregulated lipid metabolism in the prostate cancer-adipocyte crosstalk under antiandrogen therapy
    Agathe Bessot, Joan Röhl, Maria Emmerich, Anton Klotz, Akhilandeshwari Ravichandran, Christoph Meinert, David Waugh, Jacqui McGovern, Jenni Gunter, Nathalie Bock
    Materials Today Bio.2025; 30: 101424.     CrossRef
  • 3,418 View
  • 134 Download
  • 1 Web of Science
  • 1 Crossref
Close layer
Cause of Mortality after Radical Prostatectomy and the Impact of Comorbidity in Men with Prostate Cancer: A Multi-institutional Study in Korea
Sahyun Pak, Dalsan You, In Gab Jeong, Dong-Eun Lee, Sung Han Kim, Jae Young Joung, Kang-Hyun Lee, Jun Hyuk Hong, Choung-Soo Kim, Hanjong Ahn
Cancer Res Treat. 2020;52(4):1242-1250.   Published online July 3, 2020
DOI: https://doi.org/10.4143/crt.2020.286
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
This study aimed to examine the causes of death in Korean patients who underwent radical prostatectomy for prostate cancer and investigate the relationship between comorbidity and mortality.
Materials and Methods
We conducted a retrospective multicenter cohort study including 4,064 consecutive patients who had prostate cancer and underwent radical prostatectomy between January 1998 and June 2013. The primary endpoint of this study was all-cause mortality, and the secondary endpoints were cancer-specific mortality (CSM) and other-cause mortality (OCM). Charlson comorbidity index (CCI) was calculated to assess the comorbidities of each patient.
Results
Of 4,064 patients, 446 (11.0%) died during follow-up. The cause of death was prostate cancer in 132 patients (29.6%), other cancers in 121 patients (27.1%), and vascular disease in 57 patients (12.8%) in our cohort. The overall 10-year CSM rate was lower than the OCM rate (4.6% vs. 10.5%). The 10-year CSM rate was lower than the OCM rate in low- to intermediate-risk group patients (1.2% vs. 10.6%), whereas they were similar in high-risk group patients (11.8% vs. 10.1%). In the multivariable analysis, CCI was independently associated with all-cause mortality after radical prostatectomy, regardless of age and pathologic features.
Conclusion
Death from prostate cancer was rare in Korean men who underwent radical prostatectomy. Clinicians should be aware of the possibility of overtreatment of low-risk prostate cancer in men with significant comorbidity. Our findings may help to facilitate counseling and plan management in this patient group.
  • 7,095 View
  • 111 Download
  • 3 Web of Science
Close layer
Selection Criteria for Active Surveillance of Patients with Prostate Cancer in Korea: A Multicenter Analysis of Pathology after Radical Prostatectomy
Chang Wook Jeong, Sung Kyu Hong, Seok Soo Byun, Seong Soo Jeon, Seong Il Seo, Hyun Moo Lee, Hanjong Ahn, Dong Deuk Kwon, Hong Koo Ha, Tae Gyun Kwon, Jae Seung Chung, Cheol Kwak, Hyung Jin Kim
Cancer Res Treat. 2018;50(1):265-274.   Published online April 14, 2017
DOI: https://doi.org/10.4143/crt.2016.477
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Korean patients with prostate cancer (PC) typically present with a more aggressive disease than patients in Western populations. Consequently, it is unclear if the current criteria for active surveillance (AS) can safely be applied to Korean patients. Therefore, this study was conducted to define appropriate selection criteria for AS for patients with PC in Korea.
Materials and Methods
We conducted a multicenter retrospective study of 2,126 patients with low risk PC who actually underwent radical prostatectomy. The primary outcome was an unfavorable disease, which was defined by non-organ confined disease or an upgrading of the Gleason score to ≥ 7 (4+3). Predictive variables of an unfavorable outcome were identified by multivariate analysis using randomly selected training samples (n=1,623, 76.3%). We compared our selected criteria to various Western criteria for the primary outcome and validated our criteria using the remaining validation sample (n=503, 23.7%).
Results
A non-organ confined disease rate of 14.9% was identified, with an increase in Gleason score ≥ 7 (4+3) of 8.7% and a final unfavorable disease status of 20.8%. The following criteria were selected: Gleason score ≤ 6, clinical stage T1-T2a, prostate-specific antigen (PSA) ≤ 10 ng/mL, PSA density < 0.15 ng/mL/mL, number of positive cores ≤ 2, and maximum cancer involvement in any one core ≤ 20%. These criteria provided the lowest unfavorable disease rate (11.7%) when compared to Western criteria (13.3%-20.7%), and their validity was confirmed using the validation sample (5.9%).
Conclusion
We developed AS criteria which are appropriate for Korean patients with PC. Prospective studies using these criteria are now warranted.

Citations

Citations to this article as recorded by  
  • Outcomes of active surveillance for Japanese patients with prostate cancer (PRIAS‐JAPAN)
    Takuma Kato, Ryuji Matsumoto, Akira Yokomizo, Yoichiro Tohi, Hiroshi Fukuhara, Yoichi Fujii, Keiichiro Mori, Takuma Sato, Junichi Inokuchi, Katsuyoshi Hashine, Shinichi Sakamoto, Hidefumi Kinoshita, Koji Inoue, Toshiki Tanikawa, Takanobu Utsumi, Takayuki
    BJU International.2024; 134(4): 652.     CrossRef
  • Has Active Surveillance for Prostate Cancer Become Safer? Lessons Learned from a Global Clinical Registry
    Chris Bangma, Paul Doan, Lin Zhu, Sebastiaan Remmers, Daan Nieboer, Jozien Helleman, Monique J. Roobol, Mikio Sugimoto, Byung Ha Chung, Lui Shiong Lee, Mark Frydenberg, Laurence Klotz, Michael Peacock, Antoinette Perry, Anders Bjartell, Antti Rannikko, Mi
    European Urology Oncology.2024;[Epub]     CrossRef
  • Establishment of Prospective Registry of Active Surveillance for Prostate Cancer: The Korean Urological Oncology Society Database
    Gyoohwan Jung, Jung Kwon Kim, Seong Soo Jeon, Jae Hoon Chung, Cheol Kwak, Chang Wook Jeong, Hanjong Ahn, Jae Young Joung, Tae Gyun Kwon, Sung Woo Park, Seok-Soo Byun
    The World Journal of Men's Health.2023; 41(1): 110.     CrossRef
  • The Role of Magnetic Resonance Imaging (MRI) and MRI-Targeted Biopsy for Active Surveillance
    Chang Wook Jeong
    Journal of Urologic Oncology.2023; 21(2): 97.     CrossRef
  • Incidence and mortality projections for major cancers among Korean men until 2034, with a focus on prostate cancer
    Sahyun Pak, Kyu-Won Jung, Eun-Hye Park, Young Hwii Ko, Young-Joo Won, Jae Young Joung
    Investigative and Clinical Urology.2022; 63(2): 175.     CrossRef
  • Role of single nucleotide polymorphisms of the HSD3B1 gene (rs6203 and rs33937873) in the prediction of prostate cancer risk
    Yasmine Amrousy, Hesham Haffez, Doaa Abdou, Hanaa Atya
    Molecular Medicine Reports.2022;[Epub]     CrossRef
  • A single-center long-term experience of active surveillance for prostate cancer: 15 years of follow-up
    Sang Hun Song, Jung Kwon Kim, Hakmin Lee, Sangchul Lee, Sung Kyu Hong, Seok-Soo Byun
    Investigative and Clinical Urology.2021; 62(1): 32.     CrossRef
  • The clinical impact of strict criteria for active surveillance of prostate cancer in Korean population: Results from a prospective cohort
    Jungyo Suh, Hyeong Dong Yuk, Minyong Kang, Bum Sik Tae, Ja Hyeon Ku, Hyeon Hoe Kim, Cheol Kwak, Chang Wook Jeong
    Investigative and Clinical Urology.2021; 62(4): 430.     CrossRef
  • Comparison of Characteristics, Follow-up and Outcomes of Active Surveillance for Prostate Cancer According to Ethnicity in the GAP3 Global Consortium Database
    Kerri Beckmann, Aida Santaolalla, Jozien Helleman, Peter Carroll, Byung Ha Chung, Lui Shiong Lee, Antoinette Perry, Jose Rubio-Briones, Mikio Sugimoto, Bruce Trock, Riccardo Valdagni, Prokar Dasgupta, Mieke Van Hemelrijck, Oussama Elhage, Bruce Trock, Beh
    European Urology Open Science.2021; 34: 47.     CrossRef
  • Patients with Biopsy Gleason Score 3 + 4 Are Not Appropriate Candidates for Active Surveillance
    Juhyun Park, Sangjun Yoo, Min Chul Cho, Chang Wook Jeong, Ja Hyeon Ku, Cheol Kwak, Hyeon Hoe Kim, Hyeon Jeong
    Urologia Internationalis.2020; 104(3-4): 199.     CrossRef
  • Current status and progress of focal therapy in Asia
    Takumi Shiraishi, Osamu Ukimura
    Current Opinion in Urology.2018; 28(6): 529.     CrossRef
  • The MMP2 rs243865 polymorphism increases the risk of prostate cancer: A meta-analysis
    Kun Liu, Shuo Gu, Xuzhong Liu, Qing Sun, Yunyan Wang, Junsong Meng, Zongyuan Xu
    Oncotarget.2017; 8(42): 72933.     CrossRef
  • 9,117 View
  • 249 Download
  • 9 Web of Science
  • 12 Crossref
Close layer
Changing Patterns of Primary Treatment in Korean Men with Prostate Cancer Over 10 Years: A Nationwide Population Based Study
Jinsung Park, Beomseok Suh, Dong Wook Shin, Jun Hyuk Hong, Hanjong Ahn
Cancer Res Treat. 2016;48(3):899-906.   Published online October 20, 2015
DOI: https://doi.org/10.4143/crt.2015.212
AbstractAbstract PDFPubReaderePub
Purpose
We investigated changing patterns of primary treatment in Korean men with prostate cancer (PC) and impact of sociodemographic factors on treatment choice from a nationwide cohort over 10 years. Materials and Methods We conducted a cohort study of a 2% nationwide random sample of Korean National Health Insurance. A total of 1,382 patients who had undergone active treatments for newly diagnosed PC between 2003 and 2013 were included. Time trends in primary treatment of PC, including radical surgery, radiation therapy (RT), and androgen deprivation therapy (ADT) were analyzed.
Results
Total number of patients undergoing active treatments increased significantly (162%). Surgery cases showed the most significant increase, from 22.4% in 2003 to 45.4% in 2013, while the relative proportion of ADT showed a tendency to decrease from 60.3% in 2003 to 45.4% in 2013, and the relative proportion of RT was variable over 10 years (from 7.2% to 18.4%). While treatment patterns differed significantly according to age (p < 0.001) and income classes (p=0.014), there were differences in primary treatment according to residential area. In multinomial logistic regression analysis, older patients showed significant association with ADT or RT compared to surgery, while patients with higher income showed significant association with surgery. Conclusion Treatment pattern in Korean PC patients has changed remarkably over the last 10 years. Sociodemographic factors do affect the primary treatment choice. Our results will be valuable in overviewing changing patterns of primary treatment in Korean PC patients and planning future health policy for PC.

Citations

Citations to this article as recorded by  
  • Prognosis after radical prostatectomy in men older than 75 years: long-term results from a single tertiary center
    Jaewon Lee, Jungkeun Song, Gyoohwan Jung, Sang Hun Song, Sung Kyu Hong
    Prostate International.2024; 12(1): 15.     CrossRef
  • Is There a Difference in the Incidence of Depression between Radiation and Surgical Treatments in Patients with Prostate Cancer?
    Bum Sik Tae, Sun Tae Ahn, Jung Wan Yoo, Min Sung Song, Hoon Choi, Jae Hyun Bae, Jae Young Park
    The World Journal of Men's Health.2024; 42(1): 237.     CrossRef
  • Analysis of trend in the role of national and regional hubs in prostatectomy after prostate cancer diagnosis in the past 5 years: A nationwide population-based study
    Seong Cheol Kim, Seungbong Han, Ji Hyung Yoon, Sungchan Park, Kyung Hyun Moon, Sang Hyeon Cheon, Gyung-Min Park, Taekmin Kwon
    Investigative and Clinical Urology.2024; 65(2): 124.     CrossRef
  • Current treatment patterns within 1 year after prostate cancer diagnosis in Korean patients over 75 years old: a retrospective multicenter study
    Dong Jin Park, Ho Won Kang, Se Yun Kwon, Young Jin Seo, Kyung Seop Lee, Byung Hoon Kim, Teak Jun Shin, Won Tae Kim, Yong-June Kim, Seok Joong Yun, Sang-Cheol Lee, Jae-Wook Chung, Seock Hwan Choi, Jun Nyung Lee, Hyun Tae Kim, Tae-Hwan Kim, Eun Sang Yoo, Ta
    Prostate International.2023; 11(1): 34.     CrossRef
  • A Nationwide Study of Differences in Surgical Treatment Rates and Oncological Outcomes for Prostate Cancer according to Economic Status and Region
    Sangjun Yoo, Sohee Oh, Min Chul Cho, Hwancheol Son, Hyeon Jeong
    Cancer Research and Treatment.2023; 55(2): 652.     CrossRef
  • Outcomes of prostate cancer patients after robot-assisted radical prostatectomy compared with open radical prostatectomy in Korea
    Jaehun Jung, Gi Hwan Bae, Jae Heon Kim, Jaehong Kim
    Scientific Reports.2023;[Epub]     CrossRef
  • The Incidence of Prostate-Specific Antigen Test in a Country With a Limited Social Perception of Prostate Cancer 2006-2016: Disparities Manifested by Residential Area
    Young Hwii Ko, Byung Hoon Kim
    The Korean Journal of Urological Oncology.2022; 20(1): 43.     CrossRef
  • Conditional Relative Survival and Competing Mortality of Patients with Prostate Cancer in Korea: A Nationwide Cohort Study
    Jinsung Park, Kyungdo Han, Dong Wook Shin, Sang Hyun Park, Hyun Bin Shin
    Cancer Epidemiology, Biomarkers & Prevention.2021; 30(2): 326.     CrossRef
  • Epidemiology and genomics of prostate cancer in Asian men
    Yao Zhu, Miao Mo, Yu Wei, Junlong Wu, Jian Pan, Stephen J. Freedland, Ying Zheng, Dingwei Ye
    Nature Reviews Urology.2021; 18(5): 282.     CrossRef
  • Influence of repeated prostate-specific antigen screening on treatment pattern in a country with a limited social perception of prostate cancer: Korean national wide observational study
    Young Hwii Ko, Sang Won Kim
    Investigative and Clinical Urology.2021; 62(3): 282.     CrossRef
  • Population-wide impacts of aspirin, statins, and metformin use on prostate cancer incidence and mortality
    Hye Yeon Koo, Su-Min Jeong, Mi Hee Cho, Sohyun Chun, Dong Wook Shin, Jinsung Park
    Scientific Reports.2021;[Epub]     CrossRef
  • Changes in Patterns of Radical Prostatectomy due to Diffusion of Robotic Surgical System: A Nationwide Study Using Health Insurance Claims Data
    Jungmi Chae, Yeonmi Choi, Su-Jin Cho
    Yonsei Medical Journal.2021; 62(12): 1155.     CrossRef
  • Combined androgen blockade (CAB) versus luteinizing hormone-releasing hormone (LHRH) agonist monotherapy for androgen deprivation therapy
    Hyun Sik Park, Hyun Bin Shin, Seung Hyo Woo, Seung Hyun Jeon, Sang Hyub Lee, Seok Ho Kang, Ji Sung Shim, Dong Wook Shin, Jinsung Park
    World Journal of Urology.2020; 38(4): 971.     CrossRef
  • Variation in radiotherapy patterns of care in the radical treatment of South Australian men with non-metastatic prostate cancer between 2005–2015
    Stamati Morias, Elizabeth Buckley, Kerri Beckmann, Michael O'Callaghan, Martin Borg, Michala Short
    Radiotherapy and Oncology.2020; 145: 138.     CrossRef
  • Single-port robot-assisted radical prostatectomy with the da Vinci SP system: A single surgeon's experience
    Kwang Hyun Kim, Wan Song, Hana Yoon, Dong Hyeon Lee
    Investigative and Clinical Urology.2020; 61(2): 173.     CrossRef
  • Risk of dementia in prostate cancer survivors: A nationwide cohort study in Korea
    Jihun Kang, Dong Wook Shin, Kyungdo Han, Sang Hyun Park, Won Gu Lee, Jung Eun Yoo, Seung-Hyo Woo, Jinsung Park
    Current Problems in Cancer.2020; 44(6): 100578.     CrossRef
  • Risk of Ischemic Heart Disease and Stroke in Prostate Cancer Survivors: A Nationwide Study in South Korea
    Dong Wook Shin, Kyungdo Han, Hyun Sik Park, Seung-Pyo Lee, Sang Hyun Park, Jinsung Park
    Scientific Reports.2020;[Epub]     CrossRef
  • Health-Related Quality of Life Changes in Prostate Cancer Patients after Radical Prostatectomy: A Longitudinal Cohort Study
    Dong Wook Shin, Sang Hyub Lee, Tae-Hwan Kim, Seok Joong Yun, Jong Kil Nam, Seung Hyun Jeon, Seung Chol Park, Seung Il Jung, Jong-Hyock Park, Jinsung Park
    Cancer Research and Treatment.2019; 51(2): 556.     CrossRef
  • Medical Travel among Non-Seoul Residents to Seek Prostate Cancer Treatment in Medical Facilities of Seoul
    Jae Heon Kim, So Young Kim, Seok-Joong Yun, Jae Il Chung, Hoon Choi, Ho Song Yu, Yun-Sok Ha, In-Chang Cho, Hyung Joon Kim, Hyun Chul Chung, Jun Sung Koh, Wun-Jae Kim, Jong-Hyock Park, Ji Youl Lee
    Cancer Research and Treatment.2019; 51(1): 53.     CrossRef
  • Trends in Prostate Cancer Prevalence and Radical Prostatectomy Rate according to Age Structural Changes in South Korea between 2005 and 2015
    Hyun Young Lee, Suyeon Park, Seung Whan Doo, Won Jae Yang, Yun Seob Song, Jae Heon Kim
    Yonsei Medical Journal.2019; 60(3): 257.     CrossRef
  • Geographical Variations in Prostate Cancer Outcomes: A Systematic Review of International Evidence
    Paramita Dasgupta, Peter D. Baade, Joanne F. Aitken, Nicholas Ralph, Suzanne Kathleen Chambers, Jeff Dunn
    Frontiers in Oncology.2019;[Epub]     CrossRef
  • National practice patterns and direct medical costs for prostate cancer in Korea across a 10 year period: a nationwide population-based study using a national health insurance database
    Ho Won Kang, Seok-Joong Yun, Jae Il Chung, Hoon Choi, Jae Heon Kim, Ho Song Yu, Yun-Sok Ha, In-Chang Cho, Hyung Joon Kim, Hyun Chul Chung, Jun Sung Koh, Wun-Jae Kim, Jong-Hyock Park, Ji Youl Lee, So-Young Kim
    BMC Health Services Research.2019;[Epub]     CrossRef
  • Prognostic significance of lymphovascular invasion in patients with prostate cancer treated with postoperative radiotherapy
    Jae-Uk Jeong, Taek-Keun Nam, Ju-Young Song, Mee Sun Yoon, Sung-Ja Ahn, Woong-Ki Chung, Ick Joon Cho, Yong-Hyub Kim, Shin Haeng Cho, Seung Il Jung, Dong Deuk Kwon
    Radiation Oncology Journal.2019; 37(3): 215.     CrossRef
  • Radiotherapy in prostate cancer treatment: results of the patterns of care study in Korea
    Ah Ram Chang, Won Park
    Radiation Oncology Journal.2017; 35(1): 25.     CrossRef
  • Cause of Death in Korean Men with Prostate Cancer: an Analysis of Time Trends in a Nationwide Cohort
    Jinsung Park, Beomseok Suh, Dong Wook Shin, Jun Hyuk Hong, Hanjong Ahn
    Journal of Korean Medical Science.2016; 31(11): 1802.     CrossRef
  • 11,729 View
  • 223 Download
  • 26 Web of Science
  • 25 Crossref
Close layer
Efficacy and Safety of Everolimus in Korean Patients with Metastatic Renal Cell Carcinoma Following Treatment Failure with a Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor
Kwonoh Park, Jae-Lyun Lee, Jin-Hee Ahn, Kyoo Hyung Lee, In-Gab Jeong, Cheryn Song, Bumsik Hong, Jun Hyuk Hong, Hanjong Ahn
Cancer Res Treat. 2014;46(4):339-347.   Published online July 16, 2014
DOI: https://doi.org/10.4143/crt.2013.154
AbstractAbstract PDFPubReaderePub
Purpose
The purpose of this study is to assess the efficacy and safety of everolimus in Korean patients with metastatic renal cell carcinoma (mRCC) for whom initial treatment with a vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFr-TKI) has failed. Materials and Methods Eligible patients with mRCC (any histology) who had progressed on or were intolerant of VEGFr-TKI therapy received oral everolimus (10 mg dose once daily). Tumor response was reassessed according to Response Evaluation Criteria in Solid Tumors (RECIST). Results This study included 100 patientswith a median follow-up duration of 10.2 months, a median progression-free survival (PFS) of 4.2 months (95% confidence interval [CI], 3.4 to 5.0 months), and an overall survival of 10.1 months (95% CI, 6.9 to 13.3 months). The most common grade 3 or greater adverse events (AEs) overall were anemia (13%), pneumonitis (9%), hyperglycemia (8%), and stomatitis (6%). While the incidence of pneumonitis was similar (26 cases, 26%) to the reported incidence in Western patients, the Korean presentations were more severe: 10 patients permanently discontinued everolimus due to pneumonitis, including two deaths on treatment. Statistically significant relationships were established between biologic toxicities, hyperglycemia and anemia, and PFS (hyperglycemia vs. non-hyperglycemia: hazard ratio [HR], 0.61; p=0.055 and anemia vs. non-anemia: HR, 0.51; p=0.021). Conclusion Everolimus was effective in Korean patients with mRCC who had failed initial VEGFr-TKI therapy. While everolimus was well tolerated in general and the AE incidence of this study was similar to those of previous reports, severe pneumonitis was common. Hyperglycemia and anemia showed significant correlation with PFS and thus may be potentially useful as prognostic indicators.

Citations

Citations to this article as recorded by  
  • Resistance to Systemic Agents in Renal Cell Carcinoma Predict and Overcome Genomic Strategies Adopted by Tumor
    Veronica Mollica, Vincenzo Di Nunno, Lidia Gatto, Matteo Santoni, Marina Scarpelli, Alessia Cimadamore, Antonio Lopez-Beltran, Liang Cheng, Nicola Battelli, Rodolfo Montironi, Francesco Massari
    Cancers.2019; 11(6): 830.     CrossRef
  • Oral stomatitis and mTOR inhibitors: A review of current evidence in 20,915 patients
    L Lo Muzio, C Arena, G Troiano, A Villa
    Oral Diseases.2018; 24(1-2): 144.     CrossRef
  • 12,464 View
  • 73 Download
  • 5 Web of Science
  • 2 Crossref
Close layer
Efficacy and Safety of Docetaxel Plus Prednisolone Chemotherapy for Metastatic Hormone-Refractory Prostate Adenocarcinoma: Single Institutional Study in Korea
Jae-Lyun Lee, Jeong Eun Kim, Jin-Hee Ahn, Dae-Ho Lee, Jungshin Lee, Choung-Soo Kim, Jun Hyuk Hong, Bumsik Hong, Cheryn Song, Hanjong Ahn
Cancer Res Treat. 2010;42(1):12-17.   Published online March 31, 2010
DOI: https://doi.org/10.4143/crt.2010.42.1.12
AbstractAbstract PDFPubReaderePub
Purpose

To assess the efficacy and safety of treating Korean patients with metastatic hormone-refractory prostate cancer (HRPC) using docetaxel plus prednisolone chemotherapy.

Materials and Methods

This was a retrospective cohort study performed in 98 patients with metastatic HRPC between October 2003 and April 2008. After screening, 72 patients fit the eligibility criteria for inclusion in this study. Treatment consisted of 5 mg prednisolone twice daily and 75 mg/m2 docetaxel once every 3 weeks.

Results

Patient demographic characteristics included: median age 67 years (range, 51~86), median ECOG performance status 1 (0~2), Gleason score ≥8 in 61 patients (86%), and median serum PSA 45.5 ng/mL (range, 3.7~2,420.0). A total of 405 cycles of treatment were administered with a median 6 cycles (range, 1~20) per patient. The median docetaxel dose-intensity was 24.4 mg/m2/week (range, 17.5~25.6). A PSA response was seen in 51% of 63 evaluable patients at 12 weeks and maximal PSA decline ≥50% in 59% of 70 evaluable patients. Tumor response was evaluated in 13 patients, 4 patients achieved PR, and 5 patients had SD with a response rate of 31%. With a median follow-up duration of 23.1 months (95%CI, 16.7~29.5), the median time to PSA progression was 5.1 months (95%CI, 4.5~5.8) and median overall survival was 22.8 months (95%CI, 16.6~29.1). Nine (13%) patients experienced grade 3 or higher febrile neutropenia.

Conclusion

This chemotherapy regimen (docetaxel every 3 weeks plus prednisolone daily) demonstrated a strong response in Korean patients with metastatic HRPC, while the toxicity profile was manageable and similar to that observed in Western patients.

Citations

Citations to this article as recorded by  
  • Modulation of inflammatory mediators underlies the antitumor effect of the combination of morusin and docetaxel on prostate cancer cells
    Sana A. Fadil, Dina A.I. Albadawi, Khalid Z. Alshali, Hossam M. Abdallah, Mona M. Saber
    Biomedicine & Pharmacotherapy.2024; 180: 117572.     CrossRef
  • Effectiveness of Adding Docetaxel to Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer in Korean Real-World Practice
    Kwonoh Park, Jin Young Kim, Inkeun Park, Seong Hoon Shin, Hyo Jin Lee, Jae Lyun Lee
    Yonsei Medical Journal.2023; 64(2): 86.     CrossRef
  • Biopsy-detected Gleason grade 5 tumor is an additional prognostic factor in metastatic hormone-sensitive prostate cancer
    Bumjin Lim, Wonchul Lee, Yoon Soo Kyung, Dalsan You, In Gab Jeong, Jun Hyuk Hong, Hanjong Ahn, Choung-Soo Kim
    Journal of Cancer Research and Clinical Oncology.2022; 148(3): 727.     CrossRef
  • AN INDIAN PROSPECTIVE STUDY OF DOCETAXEL THERAPY IN CRPC: CAN PRETREATMENT FACTORS PREDICT THE RESPONSE
    Devashish Kaushal, Rajeev Sood
    INTERNATIONAL JOURNAL OF SCIENTIFIC RESEARCH.2021; : 78.     CrossRef
  • A prospective phase-II trial of biweekly docetaxel plus androgen deprivation therapy in patients with previously-untreated metastatic castration-naïve prostate cancer
    Seonggyu Byeon, Hongsik Kim, Hwang Gyun Jeon, Seong Il Seo, Seong Soo Jeon, Hyun Moo Lee, Soon Il Lee, Se Hoon Park
    BMC Cancer.2021;[Epub]     CrossRef
  • Efficacy of cisplatin combined with topotecan in patients with advanced or recurrent ovarian cancer as second- or higher-line palliative chemotherapy
    Myung-Won Lee, Hyewon Ryu, Ik-Chan Song, Hwan-Jung Yun, Deog-Yeon Jo, Young Bok Ko, Hyo-Jin Lee
    Medicine.2020; 99(17): e19931.     CrossRef
  • A retrospective feasibility study of biweekly docetaxel in patients with high-risk metastatic castration-naïve prostate cancer
    Sang Eun Yoon, Youjin Kim, Jangho Cho, Minyong Kang, Hyun Hwan Sung, Hwang Gyun Jeon, Byoung Chang Jeong, Seong Il Seo, Seong Soo Jeon, Hyun Moo Lee, Han Yong Choi, Su Jin Lee, Se Hoon Park
    BMC Urology.2019;[Epub]     CrossRef
  • Effect of docetaxel on the regulation of proliferation and apoptosis of human prostate cancer cells
    Chongyi Yang, Weijie Zhang, Jie Wang, Pengpeng Chen, Jiangjiang Jin
    Molecular Medicine Reports.2019;[Epub]     CrossRef
  • Impact of early changes in serum biomarkers following androgen deprivation therapy on clinical outcomes in metastatic hormone-sensitive prostate cancer
    Hiromi Sato, Shintaro Narita, Norihiko Tsuchiya, Atsushi Koizumi, Taketoshi Nara, Sohei Kanda, Kazuyuki Numakura, Hiroshi Tsuruta, Atsushi Maeno, Mitsuru Saito, Takamitsu Inoue, Shigeru Satoh, Kyoko Nomura, Tomonori Habuchi
    BMC Urology.2018;[Epub]     CrossRef
  • A retrospective feasibility study of biweekly, reduced-dose docetaxel in Asian patients with castrate-resistant, metastatic prostate cancer
    Hae Su Kim, Ji Yun Lee, Su Jin Lee, Ho Yeong Lim, Hyun Hwan Sung, Hwang Gyun Jeon, Byong Chang Jeong, Seong Il Seo, Seong Soo Jeon, Hyun Moo Lee, Han-Yong Choi, Se Hoon Park
    BMC Urology.2017;[Epub]     CrossRef
  • Clinical Outcomes of Continuous Addition of Androgen Deprivation Therapy During Docetaxel Chemotherapy for Patients With Castration-Resistant Prostate Cancer
    Dong Hoon Lee, Jung Ho Kim, Won Ik Seo, Jong Kil Nam, Tae Nam Kim, Cheol Kyu Oh, Soo Dong Kim, Sung-Woo Park, Jae Sung Chung, Sang Hyun Park, Wan Lee, Gyung Tak Sung, Moon Kee Chung, Jae Il Chung
    The Korean Journal of Urological Oncology.2017; 15(2): 59.     CrossRef
  • Hormonal therapy and chemotherapy for advanced prostate cancer
    Jae Lyun Lee
    Journal of the Korean Medical Association.2015; 58(1): 30.     CrossRef
  • Gemcitabine–oxaliplatin plus prednisolone is active in patients with castration-resistant prostate cancer for whom docetaxel-based chemotherapy failed
    J-L Lee, J-H Ahn, M K Choi, Y Kim, S-W Hong, K-H Lee, I-G Jeong, C Song, B-S Hong, J H Hong, H Ahn
    British Journal of Cancer.2014; 110(10): 2472.     CrossRef
  • Effectiveness and safety of cabazitaxel plus prednisolone chemotherapy for metastatic castration-resistant prostatic carcinoma: data on Korean patients obtained by the cabazitaxel compassionate-use program
    Jae-Lyun Lee, Se Hoon Park, Su-Jin Koh, Se Hoon Lee, Yu Jung Kim, Yoon Ji Choi, Jihye Lee, Ho Yeong Lim
    Cancer Chemotherapy and Pharmacology.2014; 74(5): 1005.     CrossRef
  • Predictive Factors for Neutropenia after Docetaxel-Based Systemic Chemotherapy in Korean Patients with Castration-Resistant Prostate Cancer
    Whi-An Kwon, Tae Hoon Oh, Jae Whan Lee, Seung Chol Park
    Asian Pacific Journal of Cancer Prevention.2014; 15(8): 3443.     CrossRef
  • Clinical predictor of survival following docetaxel-based chemotherapy
    HSIANG-YING LEE, WEN-JENG WU, CHUN-HSIUNG HUANG, YII-HER CHOU, CHUN-NUNG HUANG, YUNG-CHIN LEE, KAI-FU YANG, MEI-HUI LEE, SHU-PIN HUANG
    Oncology Letters.2014; 8(4): 1788.     CrossRef
  • Prostate-specific antigen response rate of sequential chemotherapy in castration-resistant prostate cancer: the results of real life practice
    Geehyun Song, Chunwoo Lee, Dalsan You, In Gab Jeong, Jun Hyuk Hong, Hanjong Ahn, Choung-Soo Kim
    Prostate International.2013; 1(3): 125.     CrossRef
  • Quimioterapia sistémica basada en docetaxel en hombres coreanos mayores con cáncer de próstata resistente a la castración
    S.C.H. Park, L.J. Whan, R.J. Sik
    Actas Urológicas Españolas.2012; 36(7): 425.     CrossRef
  • Docetaxel-based systemic chemotherapy in elderly Korean men with castration-resistant prostate cancer
    S.C.H. Park, L.J. Whan, R.J. Sik
    Actas Urológicas Españolas (English Edition).2012; 36(7): 425.     CrossRef
  • 11,582 View
  • 73 Download
  • 19 Crossref
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP